Fundraising Fox

Aytu Bioscience

Englewood, US · Delaware corporation · 1 known investors

Biopharmaceutical company that went public on NASDAQ in 2021 (AADI)

Biotech

Founders & leadership

JT
Jarrett T. DisbrowExecutive
JR
Joshua R. DisbrowExecutive
GA
Gregory A. GouldExecutive

Board

MM
Michael MacalusoBoard director

Investors · 1

Decheng CapitalMenlo Park

Reported raises · per SEC filings

Form D private placements

$28.8M disclosed across 4 rounds · 2015–2019

▶$10MraisedOct 2019 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Gary CantrellDirector
  • Steven BoydDirector
  • Carl DockeryDirector
  • Josh DisbrowDirector, Executive Officer
  • Jarrett DisbrowExecutive Officer
  • Ketan MehtaDirector
  • Michael MacalusoDirector
  • John Donofrio Jr.Director
  • David GreenExecutive Officer
Offering amount
$10M
Amount sold
$10M
Sales commissions
$800K
Placement agents
Ladenburg Thalmann & Co. Inc.
First sale
Oct 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.8MraisedAug 2017 · 70 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael MacalusoDirector
  • Gary V. CantrellDirector
  • Gregory A. GouldExecutive Officer
  • John A. Donofrio, Jr.Director
  • Jarrett T. DisbrowExecutive Officer
  • Joshua R. DisbrowExecutive Officer, Director
  • Carl C. DockeryDirector
Offering amount
$11.8M
Amount sold
$11.8M
Sales commissions
$1.1M
Placement agents
Joseph Gunnar & Co., LLC, Fordham Financial Management, Inc.
First sale
Aug 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.8MraisedMay 2017 · 16 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael MacalusoDirector
  • Joshua R. DisbrowExecutive Officer, Director
  • Jarrett T. DisbrowExecutive Officer
  • Gregory A. GouldExecutive Officer
  • Carl C. DockeryDirector
  • Gary V. CantrellDirector
  • John A. Donofrio, Jr.Director
Amount sold
$1.8M
First sale
May 2017
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.2MraisedSep 2015 · 96 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jarrett T. DisbrowExecutive Officer
  • Michael MacalusoDirector
  • Joshua R. DisbrowExecutive Officer
  • Gregory A. GouldExecutive Officer
Offering amount
$6M
Amount sold
$5.2M
Sales commissions
$244K
Placement agents
Newbridge Securities Corporation
First sale
Aug 2015
Incorporated
Corporation, Colorado
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Aytu Bioscience do?
Biopharmaceutical company that went public on NASDAQ in 2021 (AADI)
Who are Aytu Bioscience's investors?
Aytu Bioscience's investors include Decheng Capital.
How much funding has Aytu Bioscience raised?
Aytu Bioscience has disclosed $28.8M raised across 4 rounds.
Where is Aytu Bioscience headquartered?
Aytu Bioscience is headquartered in Englewood, US.